- $924.37m
- $891.53m
- $321.48m
- 81
- 38
- 84
- 76
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 299 | 248 | 259 | 268 | 321 |
Cost of Revenue | |||||
Gross Profit | 256 | 209 | 215 | 220 | 267 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 320 | 302 | 264 | 283 | 284 |
Operating Profit | -21.2 | -53.6 | -5.04 | -14.7 | 37.1 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -25.6 | -61.5 | -10 | -19.7 | 30.6 |
Provision for Income Taxes | |||||
Net Income After Taxes | -25.6 | -49.3 | -10.3 | -20 | 67.4 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -25.6 | -49.3 | -10.3 | -30.2 | 58.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -25.6 | -83.3 | -16.4 | -36.8 | 53.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.168 | -0.357 | -0.126 | -0.165 | 0.45 |